Description

Technical Parameters

Introduction

raws

Factory 2

product-1400-1400

Products Description

1. Basic Overview and Core Positioning

Testosterone Sustanon (SUS250) is a compound steroid raw material powder based on testosterone derivatives. Its core value lies in the synergistic effect of multiple ester components to achieve long-lasting androgen release. As a typical drug in the field of clinical hormone replacement therapy and illegal sports enhancement, its raw material powder form is a key intermediate for the preparation of injections. The powder forms a unique pharmacokinetic characteristic through the precise ratio of four testosterone fatty acid esters, which is highly controversial in the medical and sports circles.

2. Composition and proportion characteristics of ingredients

(I) Analysis of quaternary ester ingredients

SUS250 raw material powder is made of four testosterone esters mixed in a specific ratio. The molecular structure and functional positioning of each component are as follows:

1. Testosterone propionate (CAS No. 57-85-2)

◦ Content: 30% (mass percentage)

◦ Structural characteristics: 17β-hydroxyl of testosterone molecule is esterified with propionic acid (C3 fatty acid) to form short-chain esters

◦ Action characteristics: low fat solubility, rapid dissolution and absorption after injection, peak blood concentration appears in 24-48 hours, responsible for the rapid increase of initial testosterone concentration

1. Testosterone phenylpropionate (CAS No. 1255-49-8)

◦ Content: 24%

◦ Structural characteristics: propionic acid chain introduces benzene ring (C3 + benzene ring), molecular weight increases to 402.54 g/mol

◦ Action characteristics: moderate fat solubility, absorption rate between fast and medium, peak occurs in 4-7 days, maintains medium-term androgen level

1. Testosterone Isocaproate (CAS No. 15262-86-9)

◦ Content: 24%

◦ Structural characteristics: esterified with isocaproic acid (C6 branched fatty acid), the molecular volume is further increased

◦ Action characteristics: medium to high fat solubility, slow absorption rate, peak occurs in 7-10 days, plays a bridge role in sustained release

1. Testosterone Decanoate (CAS No. 5721-91-5)

◦ Content: 40% (highest proportion)

◦ Structural characteristics: connects with decanoic acid (C10 straight-chain fatty acid) to form long-chain esters, molecular weight of 484.68 g/mol

◦ Action characteristics: high fat solubility, forms a sustained-release reservoir in muscle tissue, peak occurs in 10-14 days, and the effect lasts for 2-4 Weeks, ensuring long-term androgen supply

(II) Ratio design principle

The gradient ratio of the four esters (short chain 30% + medium chain 48% + long chain 40%) follows the "fast release - sustained release" kinetic model:

• Fast release part (propionate): quickly activates androgen receptors and relieves acute testosterone deficiency symptoms

• Medium release part (phenylpropionate + isocaproate): maintains the concentration in the therapeutic window to avoid excessive fluctuations

• Sustained release part (decanoate): forms a long-term drug reservoir to reduce the frequency of administration

This design makes the blood drug concentration curve after a single injection present a "double peak - platform" feature, with the first peak (30ng/mL) appearing at 48 hours, then falling back to the steady-state concentration (15-20ng/mL) and maintained for 21 days.

3. In-depth analysis of physical and chemical properties

(I) Appearance and sensory properties

• Color: pure white to off-white crystalline powder, highly uniform snow-like particles when purity ≥98%, impurities (such as isomers) will cause slight yellowing

• Odor: no characteristic odor, only releases a weak fatty acid ester smell when dissolved at high temperature or solvent

• Particle size distribution: through 80-120 mesh sieve (180-150μm), the powder has good fluidity, and the particle size distribution uniformity can be tested by HPLC

(II) Key chemical properties

1. Solubility

◦ Lipid solubility: easily soluble in organic solvents such as ethanol (50mg/mL), olive oil (30mg/mL), benzyl benzoate (solubilizing excipient), insoluble in water

◦ Solvent dependence: castor oil or sesame oil is required as a carrier in injections, and the lipid solubility of esters is used to achieve the intramuscular depot effect

1. Stability

◦ Thermal stability: melting point range 110-120℃ (melting point difference of each ester is ≤5℃), stored at 2-8℃ in dark conditions, can be stored for 36 months

◦Chemical degradation: When exposed to strong light or alkaline environment, the ester bond may hydrolyze to generate free testosterone and fatty acids. HPLC detection shows that the impurity rate increases by ≤0.3% per month

1. Spectral characteristics

◦UV absorption: There is a strong absorption peak at 240nm (conjugated double bond of testosterone parent nucleus), and the purity can be initially screened by ultraviolet spectrophotometry

◦Infrared spectrum: 1735cm⁻¹ (ester carbonyl), 3400cm⁻¹ (hydroxyl), 1610cm⁻¹ (benzene ring skeleton, only phenylpropionic acid ester) are characteristic absorption peaks

4. Core advantages and technical value

(I) Pharmacokinetic advantages

1. Long-term sustained-release characteristics

Compared with monoester drugs (such as testosterone enanthate, which needs weekly injection), SUS250 extends the dosing interval to 2-4 through multi-ester synergy Week, patient compliance increased by more than 60%, especially suitable for hormone replacement therapy population in remote areas or with limited mobility.

2. Concentration fluctuation suppression

Single decanoate may cause blood drug concentration to drop by 20% in the third week, while SUS250's medium-chain esters are continuously supplemented during the sustained-release period, so that the concentration fluctuation range is controlled within ±15%, reducing the risk of excessive androgen (acne, hair loss) or too low (fatigue, loss of libido).

(II) Clinical application advantages

1. Broad spectrum of indications

Can be used to treat:

◦Primary hypogonadism (Klinefelter syndrome, etc.)

◦Secondary testosterone deficiency (hypopituitarism)

◦Chronic disease-related muscle atrophy (adjuvant treatment of cancer cachexia)

◦Androgen deficiency syndrome (ADAM) in middle-aged and elderly men

1. Dose flexibility

By adjusting the injection interval (2-4 weeks) or single dose (125-500mg), the testosterone baseline level of different patients can be accurately matched. For example, 250mg/2 weeks is commonly used in younger patients (20-35 years old), while 250mg/4 weeks is recommended for older patients (60+ years old).

(III) Advantages of preparation process

Powder form is convenient for:

• Aseptic freeze-drying preparation: Water-insoluble characteristics avoid the introduction of water-soluble impurities

• Uniform mixing of compound: Nano-scale dispersion of four esters is achieved through airflow pulverization technology to ensure that the ratio deviation of each component in the injection is ≤1%

• International transportation compliance: Comply with ICH Q7 API GMP standards, and no special hazardous goods labeling is required during cold chain transportation

5. Pharmacological effects and mechanisms of action

(I) Core action pathways

1. Androgen receptor (AR) activation

Testosterone esters are hydrolyzed into free testosterone by esterases in the body. After entering the target cells, they bind to AR to form AR-testosterone complexes, which are translocated to the nucleus to regulate the expression of the following genes:

◦ Anabolic pathway: Upregulate MyoD and IGF-1 genes to promote myocyte protein synthesis (23% more efficient than monoester drugs)

◦ Anti-degradation pathway: Inhibit the ubiquitin-proteasome system and reduce muscle protein degradation

◦ Gonadal axis feedback: Negative feedback inhibits the hypothalamus-pituitary - Gonadal axis (HPGA), reducing LH/FSH secretion by 50-70%

1. Non-genomic effects

Free testosterone rapidly activates the PI3K/Akt signaling pathway through cell membrane receptors, and the membrane translocation of glucose transporter 4 (GLUT4) can be observed within 30 minutes, enhancing muscle cell energy uptake.

(II) Tissue-specific effects

Target organs

Physiological effects

Intensity of action (compared with testosterone)

Skeletal muscle

Thickening of muscle fibers and increase in muscle glycogen reserves

+40% (12 weeks of continuous action)

Bone

Promotes osteoblast activity and inhibits osteoclast differentiation

+25% (lumbar bone density)

Red blood cells

Stimulates EPO production, and hematocrit increases to 55% (risk threshold)

+35% (peak within 8 weeks)

Sebaceous glands

Promotes sebum secretion, and the incidence of acne increases by 3-5 times

Equivalent to free testosterone

6. Application areas and risk warnings

(I) Legal medical applications

1. Male hypogonadism

◦ Standard treatment regimen: 250mg/2-4 weeks, for 3-6 months, can restore serum testosterone from 8nmol/L to the normal range of 15-25nmol/L

◦ Efficacy evaluation: Treatment 4 After one week, sexual desire score (IIEF-5) increased by 40%, and muscle strength (grip test) increased by 15%

1. Special medical use

◦ AIDS-related weight loss: combined with antiretroviral therapy, it can increase weight by 2-3kg/month

◦ Osteoporosis prevention: reduce the risk of vertebral fracture by 32% (continuous use for more than 2 years)

(II) Illegal abuse scenarios

1. Sports and fitness field

◦ Typical scheme: cyclical use (8-12 weeks), the dose is often 500-1000mg/week, superimposed with other steroids (such as Dbol, Deca)

◦ Expected effect: body fat percentage decreased by 3-5%, lean body mass increased by 4-6kg (8-week cycle), but accompanied by serious health risks

1. Gender non-conforming population

Some transgender men use SUS250 for gender affirmation treatment. 250mg per month can promote the development of secondary sexual characteristics (beard growth, deeper voice), but it needs to be combined with estrogen antagonists to avoid breast development.

(III) Safety risk matrix

Risk category

Specific manifestations

Occurrence probability (long-term abuse)

Irreversible risk level

Endocrine system

Testicular atrophy (volume reduction of 40%), azoospermia

70-80%

★★★★☆

Cardiovascular system

LDL-C increased by 35%, thrombosis risk increased by 2 times

50-60%

★★★★☆

Liver system

Cholestatic jaundice, GGT increased by 2-3 times

30-40%

★★★☆☆

Reproductive system

Female masculinization (hirsutism, amenorrhea)

60-70% (female use)

★★★★☆

Psychoneural system

Androgenic rage (Aggression), sleep disorders

40-50%

★★☆☆☆

7. Summary and Outlook

Testosterone Sustanon (SUS250) The raw material powder has become a benchmark drug for long-acting androgen therapy with its innovative design of multi-ester synergy, and its "fast release-sustained release" kinetic model provides a classic paradigm for the development of compound steroids. However, the duality of legal medical value and illegal abuse risk has always placed it at the focus of strict supervision and academic controversy. In the future, with the rise of targeted androgen receptor modulators (SARMs), the clinical application of SUS250 may transform towards precision and low risk, but its abuse in the field of sports medicine still needs to be curbed through multi-dimensional measures such as strengthening supervision and popularizing risk education. For the scientific research and pharmaceutical fields, optimizing the powder particle size distribution and developing new solvent systems to reduce injection pain will become important research directions to enhance its clinical practicality.